Tanshinones that selectively block the collagenase activity of cathepsin K provide a novel class of ectosteric antiresorptive agents for bone

Tanshinones that selectively block the collagenase activity of cathepsin K provide a novel class... AbbreviationsCatKcathepsin KCTx‐Icarboxy‐terminal cross‐linking telopeptide of type 1 collagenE64(1S,2S)‐2‐(((S)‐1‐((4‐guanidinobutyl)amino)‐4‐methyl‐1‐oxopentan‐2‐yl)carbamoyl)cyclopropanecarboxylic acidGAGsglycosaminoglycansM‐CSFmacrophage colony‐stimulating factorOVXovariectomizedRANKLreceptor activator of NF‐κB ligandSEMscanning electron microscopyTRAcPtartrate‐resistant acid phosphataseZ‐FR‐MCAcarbobenzoxy‐phenylalanyl‐arginyl‐4‐methyl‐coumaryl‐7‐amideIntroductionCurrently, several mechanistically different approaches to treat osteoporosis are clinically utilized. Most of them are antiresorptive and include hormone replace therapy, selective oestrogen receptor modulators (SERMs), denosumab and bisphosphonates (Chen and Sambrook, ). Only parathyroid hormone‐related peptides are effective as anabolic compounds (Whitfield, ). The common feature of most antiresorptives is the suppression of osteoclast numbers. This can be achieved by replacing oestrogen in hormone‐deficient postmenopausal women where oestrogen plays a major role in osteoclast differentiation or mimicking an oestrogen effect with SERMs. Other antiresorptives directly reduce the number of osteoclasts by either interfering with osteoclastogenesis (denosumab) via neutralizing the receptor activator of NF‐κB ligand (RANKL) or by killing osteoclasts (bisphosphonates) via apoptosis (Baron et al., ). All these methods have various side effects. A common problem is that they unbalance the cooperation between bone‐forming osteoblasts and bone‐degrading osteoclasts, which ultimately leads to poor bone quality.Major efforts have been undertaken to circumvent the disruption of the crosstalk between bone cells. One promising approach is the selective inhibition of the bone‐resorbing enzyme without interfering with the viability of osteoclasts. The perfect target http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Pharmacology Wiley

Tanshinones that selectively block the collagenase activity of cathepsin K provide a novel class of ectosteric antiresorptive agents for bone

Loading next page...
 
/lp/wiley/tanshinones-that-selectively-block-the-collagenase-activity-of-cB5Ps1mGbB
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 The British Pharmacological Society
ISSN
0007-1188
eISSN
1476-5381
D.O.I.
10.1111/bph.14133
Publisher site
See Article on Publisher Site

Abstract

AbbreviationsCatKcathepsin KCTx‐Icarboxy‐terminal cross‐linking telopeptide of type 1 collagenE64(1S,2S)‐2‐(((S)‐1‐((4‐guanidinobutyl)amino)‐4‐methyl‐1‐oxopentan‐2‐yl)carbamoyl)cyclopropanecarboxylic acidGAGsglycosaminoglycansM‐CSFmacrophage colony‐stimulating factorOVXovariectomizedRANKLreceptor activator of NF‐κB ligandSEMscanning electron microscopyTRAcPtartrate‐resistant acid phosphataseZ‐FR‐MCAcarbobenzoxy‐phenylalanyl‐arginyl‐4‐methyl‐coumaryl‐7‐amideIntroductionCurrently, several mechanistically different approaches to treat osteoporosis are clinically utilized. Most of them are antiresorptive and include hormone replace therapy, selective oestrogen receptor modulators (SERMs), denosumab and bisphosphonates (Chen and Sambrook, ). Only parathyroid hormone‐related peptides are effective as anabolic compounds (Whitfield, ). The common feature of most antiresorptives is the suppression of osteoclast numbers. This can be achieved by replacing oestrogen in hormone‐deficient postmenopausal women where oestrogen plays a major role in osteoclast differentiation or mimicking an oestrogen effect with SERMs. Other antiresorptives directly reduce the number of osteoclasts by either interfering with osteoclastogenesis (denosumab) via neutralizing the receptor activator of NF‐κB ligand (RANKL) or by killing osteoclasts (bisphosphonates) via apoptosis (Baron et al., ). All these methods have various side effects. A common problem is that they unbalance the cooperation between bone‐forming osteoblasts and bone‐degrading osteoclasts, which ultimately leads to poor bone quality.Major efforts have been undertaken to circumvent the disruption of the crosstalk between bone cells. One promising approach is the selective inhibition of the bone‐resorbing enzyme without interfering with the viability of osteoclasts. The perfect target

Journal

British Journal of PharmacologyWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off